These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35481309)

  • 1. Tocilizumab and Baricitinib for Recovery From Acute Exacerbation of Combined Pulmonary Fibrosis and Emphysema Secondary to COVID-19 Infection: A Case Report.
    Kai Y; Matsuda M; Suzuki K; Kasamatsu T; Kajita A; Uno K; Muro S
    Cureus; 2022 Mar; 14(3):e23411. PubMed ID: 35481309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes among Hospitalized COVID-19 Patients Who Received Baricitinib or Tocilizumab in Addition to Standard of Care.
    Walker CP; Hurlock NP; Deb S
    Diseases; 2024 May; 12(5):. PubMed ID: 38785762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse of COVID-19 and Viral Evolution in a Patient With Good Syndrome: A Case Report.
    Iwasaki M; Hashimoto M; Takeuchi JS; Kusaba Y; Kimura M; Terada-Hirashima J; Sugiura W; Hojo M
    Cureus; 2024 Jan; 16(1):e52592. PubMed ID: 38371040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab and PMX-DHP have efficacy for severe COVID-19 pneumonia.
    Shinomiya S; Nakase K; Fujii A; Takahara Y; Adachi H; Okuro M; Iinuma Y; Yokoyama H; Ito T; Mizuno S
    SAGE Open Med Case Rep; 2021; 9():2050313X21991063. PubMed ID: 33796310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19.
    Masiá M; Padilla S; García JA; García-Abellán J; Navarro A; Guillén L; Telenti G; Mascarell P; Botella Á; Gutiérrez F
    Front Med (Lausanne); 2021; 8():749657. PubMed ID: 34820393
    [No Abstract]   [Full Text] [Related]  

  • 8. Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone.
    Wong CKH; Lau KTK; Au ICH; Xiong X; Chung MSH; Leung BYC; Lau EHY; Cowling BJ
    Front Pharmacol; 2022; 13():866441. PubMed ID: 35707401
    [No Abstract]   [Full Text] [Related]  

  • 9. Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.
    Syam AF; Pitoyo CW; Suhendro S; Zulkarnain B; Indrasari ND; Aditianingsih D; Irawan C; Susilo A; Rumende CM; Wijaya IP; Ibrahim F; Rasmin M; Alwi I; Makmun D
    Acta Med Indones; 2021 Apr; 53(2):194-201. PubMed ID: 34251348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study.
    Lakatos B; Szabó BG; Bobek I; Kiss-Dala N; Gáspár Z; Riczu A; Petrik B; Farkas BF; Sebestyén G; Gopcsa L; Bekő G; Sinkó J; Reményi P; Szlávik J; Mathiász D; Vályi-Nagy I
    Int J Infect Dis; 2022 Dec; 125():233-240. PubMed ID: 36328291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
    Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
    J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19-Associated Pulmonary Aspergillosis in a Patient Treated With Remdesivir, Dexamethasone, and Baricitinib: A Case Report.
    Shimada A; Ohnaka S; Kubo K; Nakashima M; Nagai A
    Cureus; 2022 Apr; 14(4):e23755. PubMed ID: 35518522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Tocilizumab vs Baricitinib in Clinical Outcomes Among Hospitalized Patients With COVID-19: Experience From a Public Hospital System in New York City.
    Sunny S; Tran A; Lee J; Abdallah M; Chaudhry N; Quale J
    Open Forum Infect Dis; 2023 Aug; 10(8):ofad426. PubMed ID: 37608917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia.
    Keiffer G; French Z; Wilde L; Filicko-O'Hara J; Gergis U; Binder AF
    Front Oncol; 2020; 10():562625. PubMed ID: 33072589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary Function and Chest Computed Tomography (CT) Scan Findings After Antifibrotic Treatment for COVID-19-Related Pulmonary Fibrosis.
    Lomanta JMJ; Quinto ML; Urquiza SC; Santiaguel JM
    Am J Case Rep; 2022 Feb; 23():e934830. PubMed ID: 35152259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis.
    Sodani P; Mucci L; Girolimetti R; Tedesco S; Monaco F; Campanozzi D; Brunori M; Maltoni S; Bedetta S; Di Carlo AM; Candoli P; Mancini M; Rebonato A; D'Adamo F; Capalbo M; Frausini G
    Respir Med Case Rep; 2020; 31():101115. PubMed ID: 32670785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PMX-DHP Therapy for Dyspnea and Deoxygenation in Severe COVID-19 Pneumonia: A Case Series.
    Kuwana T; Kinoshita K; Hirabayashi M; Ihara S; Sawada N; Mutoh T; Yamaguchi J
    Infect Drug Resist; 2021; 14():1305-1310. PubMed ID: 33854342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.